About Concord Biosciences
Concord Biosciences is a Healthcare company based in Concord (United States) founded in 1986, and was acquired by Frontage Laboratories in April 2018. CRO supporting pharmaceutical, agricultural, chemical and veterinary industries. Its chief executive, as recorded, is Cliff Croley. Its focus areas include Biopharma Outsourcing, CRO, Diversified and Bioanalytical Services. Its competitors include BioAgilytix, Evans Analytical Group and Advion; 1 of its 3 listed competitors has raised funding.
Company details
Concord Biosciences was founded in 1986 and is located in Concord, United States. Operations are conducted as a full-service Contract Research Organization serving pharmaceutical, agricultural, chemical, animal nutrition, and consumer industries. Early-stage pre-clinical research, development, and testing are supported, encompassing analytical chemistry, synthetic chemistry, radiochemistry, small-scale synthesis, and full-scale chemical development for drug and agrochemical developers.
- Headquarters Concord, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website concordbio.com
- Social LinkedIn Facebook
- Acquired by Frontage Laboratories (Apr 2018)
- Investors
- Acquired byFrontage Laboratories
(Apr 2018)
Investors in Concord Biosciences
Concord Biosciences has secured backing from 1 investor. Prominent investors backing the company include Frontage Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early drug development services are provided for pharma firms. | 2001 | frontagelab.com | Exton, United States |
Investor details for Concord Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Concord Biosciences
1 people are tracked at Concord Biosciences (1 in leadership).
| Name | Role | Group |
|---|---|---|
Cliff Croley | CEO | Leadership |
Complete people profiles for Concord Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Concord Biosciences
2 dated milestones of Concord Biosciences across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Concord Biosciences is founded.
- Exit Acquired by Frontage Laboratories.
Competitors of Concord Biosciences
Concord Biosciences has 3 listed competitors in our database, 1 of them funded. They include BioAgilytix, Evans Analytical Group and Advion.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bioagilytix.com | 2008 | Durham, United States | 446 | Large-molecule bioanalysis is provided for biologics and biosimilars development. | ||
| eag.com | 1978 | San Diego, United States | 601 | Company offering a suite of scientific services for materials, engineering, agri, and life science industries | ||
| advion.com | 1993 | Ithaca, United States | $45.64M | 54 | Microfluidics and mass spectrometry products are provided for clinical research. |
Detailed competitors of Concord Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Concord Biosciences (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Concord Biosciences
Complete news archive for Concord Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concord Biosciences
Concord Biosciences was founded in 1986.
Concord Biosciences is headquartered in Concord, United States. It is registered at Concord, New Hampshire, United States.
Cliff Croley is the CEO of Concord Biosciences, as recorded in our data.
Concord Biosciences was founded in 1986 and is located in Concord, United States. Operations are conducted as a full-service Contract Research Organization serving pharmaceutical, agricultural, chemical, animal nutrition, and consumer industries. Early-stage pre-clinical research, development, and testing are supported, encompassing analytical chemistry, synthetic chemistry, radiochemistry, small-scale synthesis, and full-scale chemical development for drug and agrochemical developers.
Concord Biosciences's top competitors include BioAgilytix, Advion and Evans Analytical Group.
Concord Biosciences has 1 investor. Key investors include Frontage Laboratories.
Yes. Concord Biosciences was acquired by Frontage Laboratories in April 2018.